Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics

SALT LAKE CITY, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic testing and precision medicine, announced that a MyRisk^® Hereditary Cancer Test with RiskScore^® study has been named in the American Journal of Human Genetics as one of its top 10 significant advances in genomic medicine. The study was selected by the Genomic Medicine Working Group at the National Human Genome Research Institute.